Osteosarcoma is a highly malignant bone tumor. It is the most common primary malignant bone cancer accounting for 15%-35% of all primary malignant bone neoplasms. It has a predilection for adolescents and young adults. Osteosarcoma can be very aggressive with rapid growth and early metastases to the lungs and bones. Chondroblastic osteosarcoma is one of the most common subtypes of osteosarcomas with percentage of 11% to 50%. It is usually diagnosed in young adults with a peak at about twenty years old. The symptoms depend on location and size of the tumor. The presentation can vary from pauci-symptomatic forms to severe pain, swelling, deformity and loss of function. The histopathological diagnosis is based on the predominance of a chondroid matrix formed in the midst of neoplastic cells. Treatment regimens for chondroblastic osteosarcoma are the same as those used for conventional osteosarcoma. Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy remain the mainstay of treatment for this tumor. Chondroblastic osteosarcoma has often a poor response to chemotherapy and an unfavorable prognosis compared to other osteosarcoma histological types. In the literature, few studies have assessed the clinical, therapeutic and prognostic factors of chondroblastic osteosarcoma.